Placebo / Duration of Treatment: mean 3.4 years

DRUG2 trials

Sponsors

Organon and Co, MERCK SHARP & DOHME PERU S.R.L.,

Conditions

NephropathyType 2 Diabetes

Phase 3

A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)

CompletedNCT00308347

Organon and CoNephropathy, Type 2 Diabetes

Start: 1996-05-31End: 2001-04-30Updated: 2022-02-15

Unknown Phase

A DOUBLE-BLIND, RANDOMLY CONTROLLED PLACEBO STUDY TO EVALUATE THE RENAL PROTECTIVE EFFECTS OF LOSARTAN IN PATIENTS WITH DIABETES MELLITUS NON-INSULIN DEPENDENTS AND NEPHROPATHY

Active, not recruitingPER-077-00

MERCK SHARP & DOHME PERU S.R.L.,

Updated: 2023-09-04

Related Papers

Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials.

2024-12-102 citations

Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.

2007-04-0120 citations